World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-56 March 2026
ISSN: 2749-3644

AGE-RELATED PHARMACOKINETIC AND PHARMACODYNAMIC VARIABILITY: CLINICAL IMPLICATIONS IN PEDIATRIC AND GERIATRIC COHORTS

Usmonova Feruza Tohirjonovna
Assistant of the Department of Clinical Pharmacology and Medical Biotechnology, Andijan State Medical Institute.

Article history:

Received: February 7th 2026
Accepted: March 6th 2026

Abstract:

The physiological evolution of the human body across the lifespan dictates profound shifts in drug disposition and target organ sensitivity. This study evaluates the precise age-dependent pharmacokinetic and pharmacodynamic parameters influencing therapeutic efficacy and adverse drug reaction rates in extreme age brackets. A prospective observational cohort study was conducted involving 245 subjects, stratified into pediatric (n=110, ages 1-12 years) and geriatric (n=135, ages >65 years) groups, to assess renal clearance anomalies and hepatic cytochrome P450 enzyme efficiency. Clinical data indicate a paradoxical physiological divergence; the geriatric cohort demonstrated a 34.2% mean reduction in glomerular filtration rate, directly correlating with prolonged elimination half-lives of hydrophilic medications, whereas the pediatric cohort exhibited accelerated phase I hepatic metabolism. Statistical analysis revealed a high incidence of polypharmacy-induced toxicity in the elderly ($p = 0.012$), juxtaposed against subtherapeutic dosing outcomes in pediatric patients due to enhanced hepatic extraction ratios. The dynamics of the observed results suggest that empirical dosage regimens, traditionally standardized for healthy adults, fail significantly when extrapolated to vulnerable age groups. Individualized pharmacological profiling, adjusting for total body water compartmentalization and age-specific receptor affinity, remains an absolute requirement to optimize clinical outcomes and mitigate iatrogenic risks.

Keywords: Clinical pharmacology, pharmacokinetics, pharmacodynamics, geriatric polypharmacy, pediatric dose adjustment, glomerular filtration rate, cytochrome P450

INTRODUCTION

Global epidemiological indices consistently reveal a high prevalence of adverse drug events among demographic extremes. The integration of pharmacotherapy within pediatric and geriatric populations presents immense clinical challenges dictated by highly variable physiological parameters. Historically, pharmacological paradigms were formulated predominantly based on clinical trials conducted on young, healthy adult male cohorts. This systemic bias generated a significant research gap within the last five years, specifically regarding the localized, population-specific variations in Cytochrome P450 (CYP) polymorphic expression and age-associated decline in renal clearance pathways. Within the scope of this study, the regional demographic served by the clinics of the Andijan State Medical Institute underscores an acute necessity to map precise pharmacokinetic deviations to prevent iatrogenic complications.

Pediatric patients are not merely "miniature adults." Their ontogeny involves profound shifts in total body water percentages, drastically altering the volume of distribution for hydrophilic medications. Conversely, the geriatric metabolic profile undergoes a continuous process of physiological attenuation. The gradual loss of lean muscle mass, concomitant expansion of adipose tissue compartments, and systemic reduction in splanchnic blood flow profoundly perturb the equilibrium of lipophilic drug distribution. A detailed quantitative evaluation of these pharmacokinetic and pharmacodynamic shifts remains incomplete in the Central Asian clinical setting. Investigating these complex biotransformational realities provides the empirical foundation necessary to restructure local clinical guidelines and mitigate the exponential risk of polypharmacy in the aging population.

MATERIALS AND METHODS

A prospective, dual-arm observational cohort study was executed over an 18-month period at the therapeutic and pediatric departments affiliated with the Andijan State Medical Institute. The study enrolled 245 patients, strictly categorized into two demographic extremes: a pediatric cohort (n=110, age range 1–12 years, median

World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-56 March 2026
ISSN: 2749-3644

age 6.4) and a geriatric cohort (n=135, age range 66–88 years, median age 74.2). Inclusion criteria mandated the administration of at least one standard renally excreted antibiotic (e.g., ceftriaxone) or hepatically metabolized cardiovascular agent (e.g., amlodipine) for a minimum of 72 hours. Exclusion criteria encompassed acute end-stage organ failure, active oncological pathology, and severe congenital metabolic anomalies to prevent confounding variables in baseline pharmacokinetic assessments.

Renal function parameters were quantified using age-specific algorithms. For the pediatric cohort, the modified Bedside Schwartz equation was applied, whereas the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula was utilized for the geriatric group to estimate Glomerular Filtration Rate (eGFR). Hepatic synthetic and metabolic function was approximated via serum albumin levels and international normalized ratio (INR) metrics, alongside standard hepatic panel testing. Statistical processing was executed using IBM SPSS Statistics software (Version 27.0). Continuous variables were expressed as M ± m (Mean ± standard error of the mean). Intergroup variance analysis utilized the independent samples Student's t-test for normally distributed variables and the Mann-Whitney U test for non-parametric data. Pearson correlation matrices evaluated the relationship between chronological age and target organ clearance parameters. The significance threshold was strictly determined at $p < 0.05$, establishing a 95% confidence interval for all diagnostic findings.

RESULTS

Empirical data indicate profound systemic disparities between the evaluated cohorts regarding both drug metabolism and elimination pathways. The physiological volume of distribution (Vd) exhibited stark divergence. In the pediatric arm, total body water comprised an average of 72.4 ± 3.1% of body mass, precipitating a significant requisite increase in mg/kg dosing for hydrophilic antimicrobial agents to achieve therapeutic minimum inhibitory concentrations. Alternatively, the geriatric cohort registered a physiological decline in total body water (down to 54.1 ± 2.8%), compounded by a 22.4% relative increase in adipose tissue mass. Consequently, the half-life (t1/2) of lipophilic sedatives and cardiovascular medications in elderly subjects was prolonged by a factor of 1.6 compared to standard adult reference ranges.

Renal hemodynamics provided the most critical variance metrics. The calculated eGFR in the geriatric group demonstrated an age-dependent physiological nephron loss, averaging 58.6 ± 7.2 mL/min/1.73m2. This represents a 34.2% reduction relative to optimal adult baselines. This clearance deficit directly correlated with elevated trough serum concentrations of renally excreted drugs (Pearson correlation $r = -0.68$, $p = 0.003$). Clinically, this translated to a 14.8% incidence rate of mild to moderate nephrotoxic events or drug-drug interactions associated with polypharmacy in elderly subjects.

In direct contrast, phase I hepatic biotransformation exhibited pronounced hyperactivity in the early pediatric demographic (specifically ages 1–4 years). Enhanced liver volume relative to total body mass resulted in accelerated Cytochrome P450 turnover. Subtherapeutic serum concentrations were detected in 18.2% of pediatric cases receiving standard weight-based dosing for hepatically cleared antiepileptic and analgesic medications ($p = 0.021$), necessitating aggressive dose titration. The dynamics of the observed results suggest that the pharmacokinetic curve inverts dynamically over the lifespan, transitioning from ultra-rapid metabolism in childhood to progressive retention and accumulation in advanced age.

DISCUSSION

The complex analytical data harvested from this cohort fundamentally challenges the utility of linear dose scaling. The observed prolongation of drug half-lives in the geriatric population is driven by a systemic pathophysiological cascade: diminished cardiac output directly reduces hepatic portal perfusion, thereby decreasing the first-pass effect and significantly elevating the systemic bioavailability of highly extracted drugs. Concurrently, the age-related decline in serum albumin synthesis (recorded at 34 ± 3.2 g/L in our geriatric group) forces a higher free, unbound fraction of highly protein-bound medications into the systemic circulation. This specific mechanism exponentially increases the risk of immediate pharmacodynamic toxicity, corroborating recent international pharmacokinetic models regarding geriatric pharmacology.

When evaluating the pediatric response, the pathophysiological narrative shifts toward ontogenic enzyme maturation. The relatively massive splanchnic bed and robust CYP3A4/CYP2D6 expression in prepubescent subjects accelerate metabolic clearance rates far beyond adult capacities on a per-kilogram basis. The subtherapeutic drug levels observed align with established physiological principles showing that hepatic extraction ratios peak dynamically during early childhood development. This mandates a hyper-vigilant therapeutic drug monitoring (TDM) protocol, particularly for medications with narrow therapeutic indices.

SCIENTIFIC NOVELTY AND PRACTICAL SIGNIFICANCE

For the first time in this specific regional cohort of the Fergana Valley, precise quantitative metrics defining the

World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-56 March 2026
ISSN: 2749-3644

intersection of biological aging and regional pharmacokinetic variability have been established. The study clearly delineates the physiological boundaries where standard posology fails. Practical recommendations for clinical implementation must immediately integrate mandatory eGFR calculations prior to prescribing renally cleared medications in patients over 65 years. For the pediatric sector, healthcare protocols must pivot from static mg/kg dosing to models incorporating body surface area and ontogenic hepatic maturity indices.

CONCLUSION

Implementing individualized pharmacokinetic profiling is no longer an academic ideal but a rigorous clinical necessity. The stark physiological divergence between pediatric hyper-metabolism and geriatric physiological decline mandates the abandonment of generalized dosage regimens. Prioritizing strict dose titration based on renal clearance estimates and hepatic metabolic capacity will fundamentally secure patient safety, drastically reduce iatrogenic polypharmacy toxicity in the elderly, and optimize therapeutic efficacy in pediatric care.

REFERENCES

1. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67-76.
2. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacokinetics and pharmacodynamics. N Engl J Med. 2003;349(12):1157-1167.
3. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38(8):843-853.
4. Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther. 2008;118(2):250-267.
5. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6-14.
6. Leeder JS, Kearns GL. Pharmacogenetics in pediatrics: implications for practice. Pediatr Clin North Am. 1997;44(1):55-77.
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
8. Mulla H. Understanding developmental pharmacokinetics. Paediatr Respir Rev. 2010;11(4):195-201.
9. Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem. 2010;17(6):571-584.
10. Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric clinical practice. J Pediatr Pharmacol Ther. 2014;19(4):262-276.
11. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56(2):163-184.
12. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4(11):1832-1843.